Increased KMT2A expression was shown in AML, and CMML patients compared to controls [54, 55], and other groups demonstrated that high KMT2A levels were associated with tumor cell proliferation and migration in solid tumors [56, 57, 58, 59]. This evidence concerns the gene KMT2A and chronic myelomonocytic leukemia.